#Enzyme Immunoassay Market Size
Explore tagged Tumblr posts
Visit Tumblr Blog
Explore Tumblr blogs with no restrictions, modern design and the best experience.
Last Seen Tumblr Blogs
Fun Fact
Tumblr is available in 18 languages.
Text
According to latest report, the global enzyme immunoassay market size was USD 18.11 billion in 2023, calculated at USD 18.82 billion in 2024 and is expected to reach around USD 26.55 billion by 2033, expanding at a CAGR of 3.9% from 2024 to 2033.
0 notes
Text
#Enzyme Immunoassay (EIA) Reagents and Devices Market share#Enzyme Immunoassay (EIA) Reagents and Devices Market size#Enzyme Immunoassay (EIA) Reagents and Devices Market trends
0 notes
Text
In Vitro Diagnostics Market Size and Regional Outlook Analysis 2024 - 2030
The global in vitro diagnostics market size is expected to reach USD 101.58 billion by 2030, according to a new report by Grand View Research, Inc. It is estimated to register a CAGR of 4.4% over the forecast period driven by the increasing geriatric population, COVID-19 pandemic, and technological advancements in diagnostics that are supporting its adoption. Technological advancements in terms of portability, accuracy, and cost-effectiveness are projected to be one of the high-impact rendering drivers. Technological advancements were further accelerated by the launch of COVID-19 IVD diagnostics and enhanced the adoption of instruments and consumables for technologies, such as PCR. Competitors in the market are increasingly adopting agreement and partnership strategies to maintain a constant flow of business for manufacturers & diagnostics for users.
These agreements are also a result of the harsh price containment strategies for government laboratories, which lowers the price in government settings. For instance, in April 2021, the Italian subsidiary of Seegene, Inc. received a USD 108.25 million tenders for public procurement for the supply of extraction reagents, as well as 7.15 million SARS-CoV-2 diagnostic tests. However, it increases the multiparty nature and complexity of the supply chain. The high prevalence of cancer and Cardiovascular Diseases (CVDs) globally is anticipated to drive diagnostic innovation to facilitate early diagnosis and meet the constantly evolving needs of consumers. Novel technologies, such as plasmonic PCR, are anticipated to commercially enter the market during the forecast period, influencing the business of existing products adversely.
Gather more insights about the market drivers, restrains and growth of the In Vitro Diagnostics Market
Detailed Segmentation:
Market Characteristics
Market growth stage is medium, and the pace of the market growth is decelerating. Decreasing demand for COVID-19 tests is hampering the growth. The market is characterized by a high degree of innovation owing to the increasing introduction of novel molecular diagnostics and immunoassay tests for multiple disease indications. Moreover, increasing demand for patient-centric tests is encouraging market players to develop technologically advanced products.
Product Insights
The reagents segment held the largest share of 65.88% of the overall revenue in 2023. The segment is expected to retain its dominance growing at the fastest CAGR from 2024 to 2030 owing to the extensive R&D initiatives undertaken by major players to develop novel reagents and test kits. For instance, in February 2023, BD received the market approval for the BD Onclarity HPV Assay to be used with the ThinPrep Pap Test in the U.S. The increasing R&D activities to enable faster cancer detection and precision medicine are allowing companies to focus on niche profitable areas in the IVD business. For instance, in March 2023, QIAGEN partnered with Servier to develop a companion diagnostic test for TIBSOVO, indicated for treating the blood cancer acute myeloid leukemia.
Technology Insights
The immunoassay segment accounted for the largest revenue share in 2023. Increasing incidence of chronic & communicable diseases and rising need for early diagnosis are among the key factors leading to an increase in demand for immunological methods, including different types of Enzyme-Linked Immunosorbent Assays (ELISAs). Moreover, key players are focused on R&D pertaining to development of new immunological diagnostic instruments and tests for IVD applications. For instance, in October 2023, Sysmex Corporation and Fujirebio Holdings, Inc. collaborated to enhance their R&D, production, clinical development, and marketing activities in immunoassay.
End-use Insights
The hospitals segment held the largest revenue share in 2023 owing to a rise in the rate of hospitalizations that require support from faster diagnostics. Moreover, the ongoing development of healthcare infrastructure and favorable initiatives taken by government bodies are anticipated to enhance the existing hospital facilities. Thus, the demand for hospital-based IVD tests is increasing. Most IVD devices are purchased by hospitals and used in significant volumes. In 2023, there are over 6,129 hospitals in the U.S. that require constant aid from IVD for critical decision-making, as IVD tests provide faster and more accurate results.
Test Location Insights
The others (lab-based tests) segment accounted for the largest revenue share in 2023. A large number of test analyses at one time and the higher accuracy of laboratory-based tests make them more reliable compared to PoC and home tests, giving segment a competitive edge over the other two segments. Moreover, the availability of tests that allow for sample collection at home and sending it to the laboratories for testing makes testing highly convenient for patients.
Application Insights
The infectious diseases segment dominated the market in 2023. The outbreak of the COVID-19 pandemic increased the segment share significantly in recent years. Moreover, key players are introducing novel testing products to improve access to high-quality, innovative laboratory services for patients & healthcare providers. For instance, in February 2023, BD received EUA from the U.S. FDA for a new molecular diagnostic combination test for SARS-CoV-2, Influenza A+B, and Respiratory Syncytial Virus (RSV). Such initiatives by key players to strengthen their presence are expected to drive market growth.
Regional Insights
North America dominated the market and accounted for a share of 42.28% in 2023. The region is estimated to retain its leading market position throughout the forecast period. The market in this region is collectively driven by factors, such as the rising incidence of chronic diseases, presence of strong players, increasing number of novel test launches, and supportive government funding. For instance, in January 2023, BD and CerTest Biotec received EUA from the U.S. FDA for a PCR test for Mpox virus detection in the U.S. Moreover, the increasing requirement for genetic testing for personalized health care, such as that for diabetes and cancer, is expected to drive market growth in North America.
Browse through Grand View Research's Clinical Diagnostics Industry Research Reports.
• The global hepatitis diagnostic market size was valued at USD 3.82 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 6.5% from 2024 to 2030.
• The global hematology diagnostics market size was valued at USD 7.54 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 6.5% from 2024 to 2030.
Key Companies & Market Share Insights
Some of the key players operating in the in vitro diagnostics market include F. Hoffmann-La Roche Ltd.; Abbott; Quest Diagnostics Inc.; and Danaher. Market players are adopting various strategies, such as new product launches, mergers & acquisitions, and partnerships, to strengthen their product portfolios and offer diverse technologically advanced & innovative products.
Key In Vitro Diagnostics (IVD) Companies:
• Abbott
• bioMérieux SA
• QuidelOrtho Corporation
• Siemens Healthineers AG
• Bio-Rad Laboratories, Inc.
• Qiagen
• Sysmex Corporation
• Charles River Laboratories
• Quest Diagnostics Incorporated
• Agilent Technologies, Inc.
• Danaher Corporation
• BD
• F. Hoffmann-La Roche Ltd.
In Vitro Diagnostics Market Segmentation
Grand View Research has segmented the global in vitro diagnostics (IVD) market report based on product, technology, application, end-use, test location, and region:
IVD Product Outlook (Revenue, USD Million, 2018 - 2030)
• Instruments
• Reagents
• Services
IVD Technology Outlook (Revenue, USD Million, 2018 - 2030)
• Immunoassay
o Instruments
o Reagents
o Services
• Hematology
o Instruments
o Reagents
o Services
• Clinical Chemistry
o Instruments
o Reagents
o Services
• Molecular Diagnostics
o Instruments
o Reagents
o Services
• Coagulation
o Instruments
o Reagents
o Services
• Microbiology
o Instruments
o Reagents
o Services
• Others
o Instruments
o Reagents
o Services
IVD Application Outlook (Revenue, USD Million, 2018 - 2030)
• Infectious Diseases
• Diabetes
• Oncology
• Cardiology
• Nephrology
• Autoimmune Diseases
• Drug Testing
• Others
IVD Test Location Outlook (Revenue, USD Million, 2018 - 2030)
• Point of Care
• Home-care
• Others
IVD End-use Outlook (Revenue, USD Million, 2018 - 2030)
• Hospitals
• Laboratory
• Home-care
• Others
IVD Regional Outlook (Revenue, USD Million, 2018 - 2030)
• North America
o U.S.
o Canada
• Europe
o UK
o Germany
o France
o Spain
o Italy
o Russia
o Denmark
o Sweden
o Norway
• Asia Pacific
o Japan
o China
o India
o South Korea
o Australia
o Thailand
o Singapore
• Latin America
o Brazil
o Mexico
o Argentina
• Middle East and Africa (MEA)
o South Africa
o Saudi Arabia
o UAE
o Kuwait
Order a free sample PDF of the In Vitro Diagnostics Market Intelligence Study, published by Grand View Research.
Recent Developments
• In December 2023, ARUP Laboratories and Medicover collaborated to provide diagnostic and healthcare services in Europe. ARUP Laboratories has developed AAV5 DetectCDx in collaboration with BioMarin Pharmaceutical Inc. to select therapies for severe hemophilia A patients
• In November 2023, Veracyte joined Illumina to develop molecular tests for decentralized IVD applications. Companies are focusing on the development of Prosigna breast cancer and Percepta nasal swab tests of Veracyte
• In October 2023, Promega Corporation announced its plan to develop and commercialize companion diagnostics kits with GSK Plc to identify cancer patients with MSI-H solid tumors
• In February 2023, Unilabs announced investing over USD 200 million in Siemens Healthineers' technology and acquiring more than 400 laboratory analyzers to strengthen its laboratory infrastructure
• In February 2023, F. Hoffmann-La Roche Ltd. collaborated with Janssen Biotech Inc. to develop companion diagnostics for targeted therapies. Companion diagnostic technologies include digital pathology, NGS, PCR, immunoassays, and immunohistochemistry
#In Vitro Diagnostics Market#In Vitro Diagnostics Market size#In Vitro Diagnostics Market share#In Vitro Diagnostics Market analysis#In Vitro Diagnostics Industry
0 notes
Text
The Carcinoembryonic Antigen Market is projected to grow from USD 1235 million in 2024 to an estimated USD 3522.944 million by 2032, with a compound annual growth rate (CAGR) of 14% from 2024 to 2032.The global Carcinoembryonic Antigen (CEA) market has been experiencing significant growth, driven by advancements in cancer diagnostics, increased prevalence of cancer worldwide, and the growing awareness of the role of biomarkers in early cancer detection. CEA is a glycoprotein involved in cell adhesion and is commonly used as a tumor marker in cancer diagnostics, particularly for colorectal cancer. This article provides an in-depth analysis of the CEA market, exploring key drivers, restraints, opportunities, and trends shaping its future trajectory.
Browse the full report at https://www.credenceresearch.com/report/carcinoembryonic-antigen-cea-market
Market Definition and Scope
Carcinoembryonic Antigen (CEA) is a biomarker that is frequently measured in blood samples to monitor cancer progression, especially in patients with colorectal, breast, pancreatic, and lung cancers. CEA levels can provide essential insights into cancer recurrence, response to therapy, and prognosis. It plays a crucial role in detecting cancer at an early stage, allowing for timely intervention and personalized treatment plans. The global CEA market encompasses various diagnostic tests, including CEA assays, kits, reagents, and instrumentation.
Key Drivers of the CEA Market
1. Rising Prevalence of Cancer: The increasing incidence of cancer globally is one of the primary factors driving the CEA market. According to the World Health Organization (WHO), cancer is the second leading cause of death worldwide, accounting for approximately 10 million deaths in 2020. Colorectal cancer, in particular, is among the most common cancers, and CEA is widely used in its diagnosis and management.
2. Advancements in Diagnostic Technologies: Technological advancements in diagnostic tools and techniques have improved the accuracy and efficiency of CEA testing. The introduction of highly sensitive immunoassays, such as enzyme-linked immunosorbent assays (ELISAs) and chemiluminescence immunoassays (CLIAs), has enhanced the ability to detect CEA levels in patients, contributing to better cancer management.
3. Growing Demand for Personalized Medicine: As the healthcare industry shifts towards personalized medicine, the demand for biomarkers like CEA is increasing. CEA testing helps in tailoring treatment strategies based on an individual’s tumor biology and response to therapy, improving treatment outcomes and reducing adverse effects.
4. Increasing Awareness and Government Initiatives: Governments and healthcare organizations worldwide are raising awareness about cancer prevention and early detection. In many countries, cancer screening programs that include CEA testing are being implemented to identify high-risk populations. This has further propelled the demand for CEA diagnostic tests.
Challenges and Restraints
1. Limited Specificity of CEA Testing: One of the primary limitations of CEA as a biomarker is its lack of specificity. Elevated CEA levels can also be observed in non-cancerous conditions such as smoking, liver disease, and inflammatory conditions. This can lead to false-positive results, complicating the diagnostic process. Consequently, CEA testing is often used in conjunction with other diagnostic tools to improve accuracy.
2. High Cost of Advanced Diagnostic Tools: The cost associated with advanced diagnostic technologies, including CEA assays, can be prohibitive for healthcare providers, especially in low- and middle-income countries. This limits the accessibility of CEA testing in certain regions, thereby restricting market growth.
3. Regulatory and Reimbursement Challenges: Regulatory approval processes and reimbursement policies for diagnostic tests vary significantly across regions. Stringent regulations and the absence of uniform reimbursement policies can hinder market growth, particularly for new entrants.
Opportunities in the CEA Market
1. Emerging Markets: Developing countries, particularly in Asia-Pacific, are witnessing a surge in healthcare infrastructure development and cancer awareness programs. These regions present significant opportunities for market expansion as healthcare providers invest in advanced diagnostic tools, including CEA testing.
2. Integration of Artificial Intelligence (AI): The integration of AI and machine learning in diagnostic tools offers promising opportunities for the CEA market. AI-powered algorithms can enhance the interpretation of CEA test results, leading to more accurate and timely diagnoses.
3. Collaboration Between Key Players: Collaborations between pharmaceutical companies, diagnostic laboratories, and research institutions can accelerate the development of innovative CEA tests and assays. Such partnerships can also help in overcoming challenges related to regulatory approvals and market penetration.
Market Segmentation
The CEA market can be segmented based on product type, application, and end-user. Product types include CEA assays, kits, reagents, and instruments. Applications of CEA testing are primarily in colorectal cancer, followed by breast, pancreatic, and lung cancers. Key end-users of CEA testing products are hospitals, diagnostic laboratories, and research institutions.
Competitive Landscape
Several key players dominate the CEA market, including Abbott Laboratories, F. Hoffmann-La Roche AG, Siemens Healthineers, and Thermo Fisher Scientific. These companies focus on product innovation, partnerships, and geographic expansion to maintain a competitive edge. For instance, Roche’s Elecsys CEA assay is a popular product in cancer diagnostics, offering high precision and reliability.
Key Player Analysis:
Abbott (U.S.)
Aviva Systems Biology Corporation
Boster Biological Technology (U.S.)
Cigna (U.S.)
Correlogic Systems, Inc. (Hong Kong)
Creative Diagnostics (U.S.)
Hoffmann-La Roche Ltd (Switzerland)
Genway Biotech, LLC. (U.S.)
Laboratory Corporation of America Holdings (U.S.)
Lee BioSolutions (U.S.)
Mayo Foundation for Medical Education and Research (MFMER) (U.S.)
Merck KGaA (Germany)
Omega Diagnostics Group PLC (U.K.)
Prospec-Tany Technogene Ltd (Israel)
Quest Diagnostics Incorporated (U.S.)
RayBiotech Life, Inc (U.S.)
Segmentation:
By Type,
Serum CEA
Tissue CEA.
By Gender,
Male
Female
By Product,
Kits,
Reagents,
Instruments
By Test,
Clinical testing
Research testing.
By End-Use,
Hospitals,
Diagnostic laboratories,
Research institutes.
By Region
North America
The U.S
Canada
Mexico
Europe
Germany
France
The U.K.
Italy
Spain
Rest of Europe
Asia Pacific
China
Japan
India
South Korea
South-east Asia
Rest of Asia Pacific
Latin America
Brazil
Argentina
Rest of Latin America
Middle East & Africa
GCC Countries
South Africa
Rest of Middle East and Africa
Browse the full report at https://www.credenceresearch.com/report/carcinoembryonic-antigen-cea-market
About Us:
Credence Research is committed to employee well-being and productivity. Following the COVID-19 pandemic, we have implemented a permanent work-from-home policy for all employees.
Contact:
Credence Research
Please contact us at +91 6232 49 3207
Email: [email protected]
Website: www.credenceresearch.com
0 notes
Text
Blood Screening Market 2023- Business Planning Research and Resources, Revenue, and Forecasts 2030
Blood Screening Market Size & Trends
The global blood screening market size was valued at USD 2.76 billion in 2022 and is anticipated to grow at a compound annual growth rate (CAGR) of 11.7% from 2023 to 2030.
Blood screening is a process in which donated blood is screened for infectious diseases such as HBV, HCV, HIV1, and HIV2. The high growth of this market is attributed to rising blood donations, an increase in the incidence of infectious diseases, and government initiatives. According to World Health Organization (WHO), 118.54 million blood donations are collected yearly. In the U.S., 6.8 million individuals donate blood annually, and 13.6 million units of red blood cells and whole blood are collected annually.
Gather more insights about the market drivers, restrains and growth of the Blood Screening Market
The market is primarily driven by the rise in the rate of disorders such as HIV, diphtheria, measles and chronic diseases such as hemophilia, cancer, and other blood-related disorders. Blood-based diagnostics are used to diagnose a wide range of diseases, including infectious diseases, cancer, and cardiovascular diseases. Serology tests detect the presence of antibodies to a specific disease-causing organism. These tests diagnose various infectious diseases, including HIV, hepatitis B, and syphilis. Molecular tests detect the presence of DNA or RNA from a specific disease-causing organism. These tests are more sensitive than serology tests and can be used to diagnose diseases at an earlier stage. Biochemical tests measure the levels of certain substances in the blood. These tests can diagnose a wide range of diseases, including diabetes, kidney disease, and liver disease.
The COVID-19 pandemic had a significant impact on the market. Although respiratory droplets are the primary means of COVID-19 virus transmission, research has shown that viral RNA may be discovered in blood samples, supporting blood screening for COVID-19 identification, hence driving the market significantly.
Blood Screening Market Segmentation
Grand View Research has segmented the global blood screening market based on technology, product, and region:
Technology Outlook (Revenue, USD Million, 2018 - 2030)
Nucleic Acid Amplification Test (NAT)
ELISA
Chemiluminescence Immunoassay (CLIA) and Enzyme Immunoassay (EIA)
Next Generation Sequencing
Western Blotting
Product Outlook (Revenue, USD Million, 2018 - 2030)
Reagent
Instrument
Regional Outlook (Revenue, USD Million, 2018 - 2030)
North America
US
Canada
Europe
UK
Germany
France
Italy
Spain
Sweden
Norway
Denmark
Asia Pacific
Japan
China
India
Australia
Thailand
South Korea
Latin America
Brazil
Mexico
Argentina
Middle East and Africa
Saudi Arabia
South Africa
UAE
Kuwait
Browse through Grand View Research's Medical Devices Industry Research Reports.
The global embolic protection devices market size was valued at USD 612.9 million in 2023 and is projected to grow at a CAGR of 8.7% from 2024 to 2030.
The global covered stent market size was estimated at USD 1.13 billion in 2023 and is projected to grow at a CAGR of 4.1% from 2024 to 2030.
Key Companies & Market Share Insights
Product launches, approvals, strategic acquisitions, and innovations are just a few of the important business strategies used by market participants to maintain and grow their global reach.
For instance, in March 2023, Abbott received U.S Food and Drug Administration (FDA) clearance for a laboratory traumatic brain injury blood test, the first commercially available lab-based test for the assessment of mild traumatic brain injuries (TBIs), commonly referred to as concussions, which will be made widely available to hospitals across the U.S. This test, which is powered by Abbott’s Alinity i laboratory tool, will enable clinicians to evaluate individuals with mild traumatic brain injuries in a timely manner.
Furthermore, in May 2023, Siemens Healthcare introduced Atellica HEMA 570 and 580 next-generation hematology analyzers, which have user-friendly interfaces and can be connected to multiple analyzers to remove workflow barriers and provide high throughput time.
Key Blood Screening Companies:
Abbott
Danaher Corporation (Beckman Coulter)
Becton Dickinson and Company
Bio-Rad Laboratories, Inc.
Hoffman-La Roche Ltd.
Grifols, S.A.
Ortho-Clinical Diagnostics, Inc.
Siemens Healthcare GmbH
Thermo Fisher Scientific, Inc.
SOFINA s.a (Biomerieux)
Order a free sample PDF of the Blood Screening Market Intelligence Study, published by Grand View Research.
0 notes
Text
Coagulation Markers Market By Product Type, By Manufacturers, By End-User And Market Trend Analysis Forecast 2033
The Coagulation Markers Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions - Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).
Learn More On The Coagulation Markers Market: https://www.thebusinessresearchcompany.com/report/coagulation-markers-global-market-report
According to The Business Research Company’s Coagulation Markers Global Market Report 2024, The coagulation markers market size is expected to see strong growth in the next few years. It will grow to $1.52 billion in 2028 at a compound annual growth rate (CAGR) of 6.9%. The growth in the forecast period can be attributed to a growing incidence of chronic diseases, rising adoption of personalized medicine, a growing global population, rising healthcare expenditures, and expansion in emerging markets. Major trends in the forecast period include the integration of AI and machine learning, the development of novel biomarkers, enhanced point-of-care technologies, automation in laboratories, wearable health technologies, telehealth and remote monitoring, and sustainable diagnostic practices.
The rise in the prevalence of blood disorders is expected to propel the growth of the coagulation markers market going forward. Blood disorders refer to a wide range of conditions that affect the blood's ability to function correctly. The prevalence of blood disorders is growing due to aging populations, increased awareness, and improved diagnostic capabilities. Coagulation markers help diagnose and manage blood disorders by assessing clotting function, identifying abnormalities, and monitoring treatment effectiveness for conditions like hemophilia and thrombosis. For instance, in May 2024, according to the Leukaemia Foundation, an Australia-based non-profit organization, currently around 135,000 people in Australia are living with a blood cancer or blood disorder, with this number projected to exceed 275,000 by 2035. Therefore, an increasing prevalence of blood disorders is driving the coagulation marker market.
Get A Free Sample Of The Report (Includes Graphs And Tables): https://www.thebusinessresearchcompany.com/sample.aspx?id=17117&type=smp
The coagulation markers market covered in this report is segmented –
1) By Product: D-Dimer Assay, Fibrinogen Assay 2) By Sample Type: Plasma, Whole Blood Sample, Other Sample Types 3) By Technology: Fluorescence Immunoassay, Enzyme-Linked Immuno Sorbent Assay (ELISA), Rapid Test, Particle Enhanced Immunoturbidimetric Assay 4) By Application: Deep Venous Thrombosis (DVT), Pulmonary Embolism (PE), Disseminated Intravascular Coagulation (DIC), Trauma, Other Applications 5) By End User: Hospital, Specialty Clinics, Academic And Research Institute, Diagnostics Laboratories
Major companies operating in the coagulation markers market are focusing on developing technologically innovative solutions, such as automated blood coagulation analyzers, to improve diagnostic accuracy, enhance efficiency, and provide faster results for better patient management. An automated blood coagulation analyzer is a medical device that automatically performs various tests to evaluate blood clotting function, providing rapid and accurate results for diagnosing and managing coagulation disorders. For instance, in July 2021, Sysmex Corporation, a Japan-based provider of in-vitro diagnostic solutions, announced the launch of its new automated blood coagulation analyzers named CN-6000 and CS-5100, designed to provide efficient and accurate coagulation testing in clinical laboratories. The CN-6000 is a fully automated coagulation analyzer with a maximum throughput of 240 tests per hour, featuring automatic sample pre-treatment, clot detection, and quality control management. The CS-5100, on the other hand, is a compact and versatile coagulation analyzer suitable for small to medium-sized laboratories, offering a throughput of up to 120 tests per hour and a user-friendly interface. Both analyzers support a wide range of coagulation assays and are designed to streamline coagulation testing workflows, improve turnaround times, and enhance patient care in clinical laboratories.
The coagulation markers market report table of contents includes:
1. Executive Summary
2. Coagulation Markers Market Characteristics
3. Coagulation Markers Market Trends And Strategies
4. Coagulation Markers Market - Macro Economic Scenario
5. Global Coagulation Markers Market Size and Growth ............
32. Global Coagulation Markers Market Competitive Benchmarking
33. Global Coagulation Markers Market Competitive Dashboard
34. Key Mergers And Acquisitions In The Coagulation Markers Market
35. Coagulation Markers Market Future Outlook and Potential Analysis
36. Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
0 notes
Text
0 notes
Text
Chemiluminescence Immunoassay (CLIA) Market Application, CAGR Status, Growth 2024-2032
The Reports and Insights, a leading market research company, has recently releases report titled “Chemiluminescence Immunoassay (CLIA) Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2024-2032.” The study provides a detailed analysis of the industry, including the global Chemiluminescence Immunoassay (CLIA) Market share, size, trends, and growth forecasts. The report also includes competitor and regional analysis and highlights the latest advancements in the market.
Report Highlights:
How big is the Chemiluminescence Immunoassay (CLIA) Market?
As per Reports and Insights Analysis, the chemiluminescence immunoassay (CLIA) market is expected to grow at a CAGR of 7.8% during the forecast period of 2024 to 2032.
What are Chemiluminescence Immunoassay (CLIA)?
Chemiluminescence immunoassay (CLIA) is a highly sensitive laboratory technique used to identify specific proteins or substances in a sample, such as hormones, antibodies, or antigens. It relies on chemiluminescence, a process where a chemical reaction produces light. In CLIA, this reaction occurs when a labeled molecule, like an enzyme or a fluorophore, attached to an antibody or antigen binds to the target substance. The emitted light is then measured by a sensitive detector, with the intensity of the light directly proportional to the amount of the target substance in the sample. Due to its high sensitivity and specificity, CLIA is extensively used in clinical laboratories for disease diagnosis, therapeutic drug monitoring, and research purposes.
Request for a sample copy with detail analysis: https://www.reportsandinsights.com/sample-request/1671
What are the growth prospects and trends in the Chemiluminescence Immunoassay (CLIA) industry?
The chemiluminescence immunoassay (CLIA) market growth is driven by various factors. The market for chemiluminescence immunoassays (CLIA) is experiencing notable growth, fueled by increasing demand for precise and sensitive diagnostic tests. CLIA's advantages include high sensitivity, a broad dynamic range, and excellent specificity, making it well-suited for detecting various biomarkers in clinical diagnostics and research. Factors such as the rising prevalence of chronic and infectious diseases, a growing elderly population, and increased demand for quick and dependable diagnostic tests are propelling market expansion. Furthermore, technological advancements, like automated CLIA systems, are also contributing to market growth. Hence, all these factors contribute to chemiluminescence immunoassay (CLIA) market growth.
What is included in market segmentation?
The report has segmented the market into the following categories:
By Product Type:
Analyzers
Reagents & Consumables
By Analyzer Type:
Benchtop Analyzers
Floor-standing Analyzers
By Application:
Infectious Diseases
Oncology
Cardiology
Autoimmune Diseases
Others
By End-Use:
Hospitals & Diagnostic Laboratories
Research & Academic Institutes
Pharmaceutical & Biotechnology Companies
Contract Research Organizations (CROs)
Segmentation By Region:
North America:
United States
Canada
Asia Pacific:
China
India
Japan
Australia & New Zealand
Association of Southeast Asian Nations (ASEAN)
Rest of Asia Pacific
Europe:
Germany
The U.K.
France
Spain
Italy
Russia
Poland
BENELUX (Belgium, the Netherlands, Luxembourg)
NORDIC (Norway, Sweden, Finland, Denmark)
Rest of Europ
Latin America:
Brazil
Mexico
Argentina
Rest of Latin America
The Middle East & Africa:
Saudi Arabia
United Arab Emirates
South Africa
Egypt
Israel
Rest of MEA (Middle East & Africa)
Who are the key players operating in the industry?
The report covers the major market players including:
Roche Diagnostics
Siemens Healthineers
Abbott Laboratories
Beckman Coulter (a subsidiary of Danaher Corporation)
Ortho Clinical Diagnostics
bioMérieux SA
DiaSorin S.p.A.
Sysmex Corporation
Thermo Fisher Scientific Inc.
Mindray Bio-Medical Electronics Co., Ltd.
Randox Laboratories Ltd.
Snibe Diagnostic
View Full Report: https://www.reportsandinsights.com/report/Chemiluminescence Immunoassay (CLIA)-market
If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.
About Us:
Reports and Insights consistently mееt international benchmarks in the market research industry and maintain a kееn focus on providing only the highest quality of reports and analysis outlooks across markets, industries, domains, sectors, and verticals. We have bееn catering to varying market nееds and do not compromise on quality and research efforts in our objective to deliver only the very best to our clients globally.
Our offerings include comprehensive market intelligence in the form of research reports, production cost reports, feasibility studies, and consulting services. Our team, which includes experienced researchers and analysts from various industries, is dedicated to providing high-quality data and insights to our clientele, ranging from small and medium businesses to Fortune 1000 corporations.
Contact Us:
Reports and Insights Business Research Pvt. Ltd. 1820 Avenue M, Brooklyn, NY, 11230, United States Contact No: +1-(347)-748-1518 Email: [email protected] Website: https://www.reportsandinsights.com/ Follow us on LinkedIn: https://www.linkedin.com/company/report-and-insights/ Follow us on twitter: https://twitter.com/ReportsandInsi1
#Chemiluminescence Immunoassay (CLIA) Market share#Chemiluminescence Immunoassay (CLIA) Market size#Chemiluminescence Immunoassay (CLIA) Market trends
0 notes
Text
Protein Production Technologies Outlines, Future Trends, Insight And Quality Analysis
Protein production technologies represent the backbone of modern biotechnology, driving innovation across multiple industries including pharmaceuticals, agriculture, and biomanufacturing. .
The Protein Production Technologies was valued at $2,393.0 million in 2023 and is expected to reach $6,963.6 million by 2033, growing at a CAGR of 11.27% between 2023 and 2033
Gene Expression Analysis Overview
Protein production technologies encompass a diverse array of methodologies, tools, and techniques utilized to generate proteins for various applications in research, medicine, industry, and beyond. These technologies are designed to efficiently produce recombinant proteins, peptides, and other biomolecules, either in living organisms (in vivo) or in laboratory settings (in vitro).
In vivo protein production technologies typically involve genetically engineering host organisms, such as bacteria, yeast, insect cells, or mammalian cells, to express specific proteins of interest. This can be achieved through the use of expression vectors containing the gene encoding the target protein, along with regulatory elements to drive its expression.
Market Segmentation
Segmentation 1: By Application
Segmentation 2: By End User
Segmentation 3: By Product
Segmentation 4: By Expression System
Segmentation 5: By Region
Protein expression in North America is a dynamic and crucial field with a significant impact across industries.
The region, especially North America, is a global leader in biopharmaceuticals, relying extensively on protein expression for producing biologics, including monoclonal antibodies and vaccines.
North America holds the largest share of the Protein Production Technologies
Download our sample page now click here !
Application for Recombinant Protein Production Technologies
Drug Discovery
Structural Biology
Disease Modelling
Enzyme Production
Vaccines Development
Therapeutic Proteins
Immunoassays
Key Market Players
Agilent Technologies, Inc.
Bio-Rad Laboratories, Inc.
Charles River Laboratories International, Inc.
Danaher Corporation (Abcam plc.)
GenCefe Co., Ltd.
Genscript Biotech Corporation
And many others
Market Dynamics
Market Drivers
Increasing Demand for Protein Biologics Creating the Need for Protein Expression
Market Restraints
Long and Complicated Regulatory Timelines and Approvals of Recombinant Proteins and Biologics
Market Opportunities
Rising Awareness of Proteomics in Emerging Countries
Visit our Life Sciences & Biopharma page for better understanding
Key factors contributing to the growth of the recombinant Protein Production Technologies
Expanding applications of recombinant proteins in drug discovery, biomanufacturing, and diagnostic assays
Rising prevalence of chronic diseases and the need for innovative therapies.
Recent Developments in the Recombinant Protein Production Technologies
In January 2024, Evosep, a leader in sample preparation for mass spectrometry-based proteomics, partnered with Thermo Fisher Scientific Inc., a global scientific leader, to advance clinical proteomics research. This collaboration would combine Evosep's sample separation technology with Thermo Fisher Scientific Inc.'s mass spectrometry instruments, enhancing proteomics research capabilities.release would support pharmaceutical and biotechnology companies engaged in the manufacturing of therapeutic proteins, with the goal of improving product quality and expediting time-to-market.
Key Questions Answered
Q What is the estimated global market size for the Protein Production Technologies ?
Q What are the future trends expected in the Protein Production Technologies ?
Q What does the supply chain and value chain of the Protein Production Technologies look like?
Q What is the regulatory framework of the Protein Production Technologies ?
Q How has the COVID-19 outbreak affected the future trajectory of the Protein Production Technologies ?
Q What are the market entry barriers and opportunities in the Protein Production Technologies ?
Q What are the major market drivers, challenges, and opportunities of the Protein Production Technologies ?
Q How is each segment of the Protein Production Technologies expected to grow during the forecast period, and what is the anticipated revenue generated by each of the segments by the end of 2033?
Q What is the growth potential of the global Protein Production Technologies in North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World, and what are the driving and challenging factors of the market in each of these regions?
Q Who are the leading players with significant offerings in the Protein Production Technologies , and what is the current market dominance for each of these leading players? Who are the next frontiers in the Protein Production Technologies ?
Conclusion
In conclusion, the Protein Production Technologies continues to thrive and evolve as a vital component of numerous industries, including biotechnology, pharmaceuticals, agriculture, and research
0 notes
Text
Esoteric Testing Market to Witness Growth Acceleration During 2021-2033
Market Definition
Esoteric Testing involves the laboratory examination of uncommon molecules and substances that is not often done in a clinical laboratory. These tests are carried out when a doctor needs more comprehensive information regarding the patient’s health. To assess the outcome, a sophisticated device, materials, and specialist are needed.
Market Dynamics
The global esoteric testing market was valued at USD 21.4 billion in 2022 and it is anticipated to grow further up to USD 62.9 billion by 2032, at a CAGR of 11.4% during the forecast period.
To Know More@ https://www.globalinsightservices.com/reports/esoteric-testing-market/
Market Trends and Drivers
The growing geriatric population coupled with the increasing prevalence of chronic and infectious diseases and advancing esoteric DNA sequencing technologies in precision medicine, early diagnosis of cancer, and precision medicine are boosting the growth of the market. Globally, chronic diseases including diabetes, heart disease, and cancer are on the rise. Infectious disease prevalence is also rising at an alarming rate and includes diseases like Dengue, Hepatitis B, C, HIV, Malaria, Tuberculosis, and others. The knowledge of esoteric testing for the quick and accurate detection of certain disorders is growing. Esoteric tests’ improving technology is providing quicker results with improved sensitivity, detection limits, and efficacy. The market is expanding as a result of the rising use of esoteric DNA sequencing, NGS technologies, and whole genome sequencing in the early diagnosis of cancer, precision medicine, and personalized medicine.
Request Sample@ https://www.globalinsightservices.com/request-sample/GIS10283/?utm_id=1017
Research Objectives
Estimates and forecast the overall market size for the total market, across product, service type, type, end-user, and region
Detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling
Identify factors influencing market growth and challenges, opportunities, drivers and restraints
Identify factors that could limit company participation in identified international markets to help properly calibrate market share expectations and growth rates
Trace and evaluate key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities
Thoroughly analyze smaller market segments strategically, focusing on their potential, individual patterns of growth, and impact on the overall market
To thoroughly outline the competitive landscape within the market, including an assessment of business and corporate strategies, aimed at monitoring and dissecting competitive advancements.
Identify the primary market participants, based on their business objectives, regional footprint, product offerings, and strategic initiatives
Request Customization@ https://www.globalinsightservices.com/request-customization/GIS10283/
Global Esoteric Testing Market Segmentation:
By Type
Infectious Diseases Testing
Endocrinology Testing
Oncology Testing
Genetics Testing
Toxicology Testing
Immunology Testing
Neurology Testing
Others
By Technology
Chemiluminescence Immunoassay
Enzyme-Linked Immunosorbent Assay
Mass Spectrometry
Real-Time PCR
DNA Sequencing
Flow Cytometry
Others
By End User
Independent & Reference Laboratories
Hospital Based Technologies
Research Scope
Scope – Highlights, Trends, Insights. Attractiveness, Forecast
Market Sizing – Product Type, End User, Offering Type, Technology, Region, Country, Others
Market Dynamics – Market Segmentation, Demand and Supply, Bargaining Power of Buyers and Sellers, Drivers, Restraints, Opportunities, Threat Analysis, Impact Analysis, Porters 5 Forces, Ansoff Analysis, Supply Chain
Business Framework – Case Studies, Regulatory Landscape, Pricing, Policies and Regulations, New Product Launches. M&As, Recent Developments
Competitive Landscape – Market Share Analysis, Market Leaders, Emerging Players, Vendor Benchmarking, Developmental Strategy Benchmarking, PESTLE Analysis, Value Chain Analysis
Company Profiles – Overview, Business Segments, Business Performance, Product Offering, Key Developmental Strategies, SWOT Analysis.
Buy your copy here@ https://www.globalinsightservices.com/checkout/single_user/GIS10283/
With Global Insight Services, you receive:
10-year forecast to help you make strategic decisions
In-depth segmentation which can be customized as per your requirements
Free consultation with lead analyst of the report
Infographic excel data pack, easy to analyze big data
Robust and transparent research methodology
Unmatched data quality and after sales service
Contact Us:
Global Insight Services LLC 16192, Coastal Highway, Lewes DE 19958 E-mail: [email protected] Phone: +1-833-761-1700 Website: https://www.globalinsightservices.com/
About Global Insight Services:
Global Insight Services (GIS) is a leading multi-industry market research firm headquartered in Delaware, US. We are committed to providing our clients with highest quality data, analysis, and tools to meet all their market research needs. With GIS, you can be assured of the quality of the deliverables, robust & transparent research methodology, and superior service.
0 notes
Text
Understanding Market Dynamics in the Autoimmune Disease Diagnostics Market Industry
Market Overview –
The size of the market for autoimmune disease diagnostics was estimated at USD 4.9 billion in 2022 and is expected to increase at a compound yearly growth rate (CAGR) of 6.7% from USD 5.23 billion in 2023 to USD 8.78 billion by 2032.
The autoimmune disease diagnostics market is witnessing growth driven by advancements in the diagnosis of lupus and other autoimmune conditions. With increasing awareness and understanding of these diseases, there's a rising demand for accurate and efficient diagnostic tools. Innovations in biomarker testing and imaging techniques are enhancing early detection and personalized treatment strategies, driving market expansion.
The autoimmune disease diagnostics market focuses on providing tools and tests for diagnosing autoimmune diseases, a group of conditions where the immune system attacks healthy cells and tissues. These diseases can affect various organs and systems in the body, leading to chronic inflammation, tissue damage, and functional impairment.
Market growth is driven by the increasing prevalence of autoimmune diseases worldwide, attributed to factors such as genetic predisposition, environmental triggers, and lifestyle factors. With millions of people affected by autoimmune diseases, there is a growing demand for accurate and timely diagnostic tests to facilitate early intervention and improve patient outcomes.
Technological advancements and innovations in autoimmune disease diagnostics are shaping the market, offering new biomarkers, imaging techniques, and molecular assays to enhance diagnostic accuracy and precision. From serological tests and genetic testing to advanced imaging modalities and point-of-care devices, these advancements enable healthcare providers to diagnose autoimmune diseases more effectively and tailor treatment strategies to individual patient needs.
Moreover, the growing recognition of the importance of early detection and personalized medicine is driving market growth, as healthcare systems prioritize preventive healthcare and precision diagnostics to improve patient care and reduce healthcare costs.
However, challenges such as variability in disease presentation, overlapping symptoms, and limited awareness among healthcare providers pose obstacles to market growth. Addressing these challenges requires greater education and training for healthcare professionals, improved access to diagnostic tools and resources, and collaboration between industry stakeholders to develop standardized diagnostic protocols and guidelines.
Segmentation –
The global autoimmune disease diagnostics market has been segmented on the basis of disease type, test type, and end-user.
The market, by disease type, has been classified as systemic autoimmune disease, and localized autoimmune disease. The systemic autoimmune disease segment has been further classified into psoriasis, multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus (SLE), and others. Localized autoimmune disease segment has been divided into inflammatory bowel disease, thyroid, type 1 diabetes, and others.
On the basis of test type, the market has been segregated into western blotting, enzyme-linked immunosorbent assay (ELISA), double immune diffusion, dot blot, counter immune-electrophoresis, line blot, immunofluorescence assays (IFA), multiplex immunoassay, agglutination, and others.
The end-user segment has been divided into, has been segmented into hospitals, diagnostics centers, research laboratories, and others
Regional Analysis –
The autoimmune disease diagnostics market varies regionally due to differences in disease prevalence, diagnostic infrastructure, and healthcare expenditure. Developed regions like North America and Europe have a higher prevalence of autoimmune diseases and well-established diagnostic capabilities, leading to a robust market for autoimmune disease diagnostics. In contrast, developing regions face challenges such as limited access to specialized testing facilities and lower awareness of autoimmune diseases, resulting in underdiagnosis and undertreatment.
Moreover, variations in regulatory frameworks and reimbursement policies influence market dynamics across different regions. As the burden of autoimmune diseases continues to rise globally, there is a growing need for affordable and accessible diagnostic solutions, particularly in underserved regions. Collaborative efforts between healthcare stakeholders and diagnostic companies are essential to address regional disparities and improve patient outcomes in the autoimmune disease diagnostics market.
Key Players –
Autoimmune disease diagnostics companies include Siemens Healthcare Private Limited, bioMérieux SA, Bio-rad Laboratories, Beckman Coulter, AstraZeneca, EUROIMMUN AG, Hoffmann-la Roche, Inova Diagnostics, Myriad Genetics, Thermo Fisher Scientific, Trinity Biotech Plc., and Hemagen Diagnostics.
Related Reports –
Urinalysis Test
Celiac Disease Treatment
Healthcare Enterprise Software
Amniotic Membrane
For more information visit at MarketResearchFuture
#Autoimmune Disease Diagnostics Market#Autoimmune Disease Diagnostics Market Size#Autoimmune Disease Diagnostics Market Share#Autoimmune Disease Diagnostics Market Growth#Autoimmune Disease Diagnostics Market Trends
0 notes
Text
Esoteric Testing Market Industry Growth with Key Manufacturers Analysis
The Insight Partners through the latest research report titled- “ Esoteric Testing Market Statistics and Industry Analysis| 2025” brings to investors, a detailed analysis of the Esoteric Testing market from entrepreneurs’ point of view. Investigation of current market scenarios draws valuable insights for companies.
This study offers indulge into market incentives, challenges, and opportunities that businesses must not miss. As consumer-centric businesses tend to generate greater ROIs, opting for a Esoteric Testing market research would be a business recipe for success. Considering the escalated competition in the Esoteric Testing market, only creating a mere hunch of products won’t be sufficient. Market research can help businesses to predict product potential and success.
What to expect from this edition of Esoteric Testing market report?
1) Analysis of Industry Dynamics
This chapter studies different variables that characterize the Esoteric Testing market such as drivers, restraints, threats, and opportunities. Genuine determinants of markets are fostering innovations. This section focuses on how the activities of businesses are distributed and what factors influence growth. A wide spectrum of Esoteric Testing market-specific data is offered allowing initial determination of market potential.
2) Competitive Comparison Matrix
This chapter in Esoteric Testing market research aims to offer a competitive comparison matrix for companies. This section offers a complete picture of competitors' scale-ups and their business strategies. Businesses can figure out alternatives to competitors through thorough market surveys and target market insights. By learning about competition offerings, companies can discover new market niches and sales funnel. Key companies in the Esoteric Testing market are- .
3) Industry Specific COVID-19 Impact Analysis
The global health epidemic of COVID-19 brought supply demand disruption. Esoteric Testing Market players faced challenges to survive their production lifecycle, reduced revenues, and weak marketing performance. At the same time, companies faced a crunch in distribution channels due to lockdowns and transport restrictions. Small, and medium-sized companies struggled to manage expectations and hold on to supply-demand equilibrium. This section covers the impact analysis of COVID-19 on business and alternative ways used by businesses to respond to the pandemic-led disruptions. Post-Covid -19 recovery prospects are also covered in this chapter.
4) Segmentation of Esoteric Testing Market
In a competitive Esoteric Testing market, learning about key segments is essential for brands to cater to their customers. It is a powerful aspect of market research to streamline market strategies. This section under research highlights segments based on products, applications, and regions. Understanding demographics and high ROI geographical markets helps brands to further optimize their products and services.
Based on Technology of Esoteric Testing Market Research report:
Chemiluminescence Immunoassay
Real-Time PCR
Flow Cytometry
Mass Spectrometry
Enzyme-Linked Immunosorbent Assay
Based on Test Type of Esoteric Testing Market Research report:
Infectious Diseases Testing
Oncology Testing
Genetic Testing
Neurology Testing
Endocrinology Testing
Toxicology Testing
Based on End User of Esoteric Testing Market Research report:
Hospital Laboratories
Independent & Reference Laboratories
Based on Regions:
North America (U.S., Canada, Mexico)
Europe (U.K., France, Germany, Spain, Italy, Central & Eastern Europe, CIS)
Asia Pacific (China, Japan, South Korea, ASEAN, India, Rest of Asia Pacific)
Latin America (Brazil, Rest of Latin America)
The Middle East and Africa (Turkey, GCC, Rest of the Middle East and Africa)
Rest of the World…
Business Takeaways for Esoteric Testing market participants:
Resource planning insights based on value chain analysis
Product positioning strategies for new entrants in Esoteric Testing market
Leading Esoteric Testing market participants and their growth strategies
Market estimated on key geographical markets, leading participants, and product segments.
Detailed analysis of market trends covering the latest innovations.
Details on market dynamics including- market incentives, restraints, threats, and growth opportunities.
0 notes
Text
Nurse Call Systems Market Key Companies, Growth and Forecast Report, 2030
The global nurse call systems market size was valued at USD 1.7 billion in 2022 and is expected to expand at a compound annual growth rate (CAGR) of 12.11% from 2023 to 2030.
The growing need for a diverse and integrated platform that increases the preference for mobility aids are driving the market. Medicare decides to refund schemes based on quality and outcome rather than quantity owing to the rising healthcare cost. Medicare estimates that current reimbursement practices are costing an additional USD 2.1 billion and expects to curtail this by using technology-focused healthcare. With this change in reimbursement policies, hospitals and other healthcare facilities are trying to streamline their workflow processes by adopting technology-oriented nurse call systems.
Nurse call systems enable reliable and flexible communication between the patient and the caregiver. Increasing patient numbers in healthcare facilities and the introduction of advanced ways to expand communication, workflow, and management to provide quality patient care are fueling the market growth. The market is primarily driven by technological advancements that have allowed players to create innovative devices. For instance, in December 2019, Tunstall Group launched Tunstall Carecom, a wireless and digital nurse call system.
Gather more insights about the market drivers, restrains and growth of the Nurse Call Systems Market
Blood Screening Market Report Highlights
• The reagent segment accounted for the largest revenue share of around 73.0% in 2022 and is expected to grow at the fastest CAGR of 12.0% over the forecast period.
• North America dominated the market and accounted for the largest revenue share of 39.0% in 2022 owing to the presence of key industry players, increased adoption of the blood screening process, stringent FDA regulations for transfusion, rising infectious disease prevalence, and greater patient affordability are responsible for maintaining its position during the forecast period.
• Asia Pacific is expected to grow at the fastest CAGR of 13.5% over the forecast period owing to increasing awareness about blood donation, rising patient affordability, and the focus of key industry players on emerging countries in the region.
Browse through Grand View Research's Medical Devices Industry Research Reports.
• The global emergency medical services product market size was valued at USD 22.5 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 6.4% from 2024 to 2030.
• The global scanning electron microscopes market size was valued at USD 4.34 billion in 2023 and is expected to grow at a compound annual growth rate (CAGR) of 8.6% from 2024 to 2030.
Blood Screening Market Segmentation
Grand View Research has segmented the blood screening market by product, technology, and region:
Blood Screening Technology Outlook (Revenue, USD Million, 2018 - 2030)
• Nucleic Acid Amplification Test (NAT)
• ELISA
• Chemiluminescence Immunoassay (CLIA) and Enzyme Immunoassay (EIA)
• Next Generation Sequencing
• Western Blotting
Blood Screening Product Outlook (Revenue, USD Million, 2018 - 2030)
• Reagent
• Instrument
Blood Screening Regional Outlook (Revenue, USD Million, 2018 - 2030)
• North America
o U.S.
o Canada
• Europe
o UK
o Germany
o France
o Italy
o Spain
o Sweden
o Norway
o Denmark
• Asia Pacific
o Japan
o China
o India
o Australia
o Thailand
o South Korea
• Latin America
o Brazil
o Mexico
o Argentina
• Middle East and Africa
o Saudi Arabia
o South Africa
o UAE
o Kuwait
Order a free sample PDF of the Nurse Call Systems Market Intelligence Study, published by Grand View Research.
#Nurse Call Systems Market#Nurse Call Systems Market size#Nurse Call Systems Market share#Nurse Call Systems Market analysis#Nurse Call Systems Industry
0 notes
Text
ELISpot and FluoroSpot Assay Market Key Findings & Key Players: 2030
The ELISpot and FluoroSpot Assay Market is Segmented By Product (Analyzers, Assay Kits, and Ancillary Products), Application (Research and Diagnostics), End-User (Hospitals & Clinical Labs, Biopharmaceutical Companies, and Research Institutes) and region (North America, Europe, Asia-Pacific, Middle East and Africa and South America).
Market Overview
The global ELISpot and FluoroSpot Assay market size was estimated at USD 295.64 million in 2023 and is projected to reach USD 503.41 million in 2030 at a CAGR of 7.9% during the forecast period 2023-2030.
Due to its excellent sensitivity, the enzyme-linked immunospot (ELISpot) test is frequently used to identify different illness conditions. They're incredibly adaptable and frequently employed to gauge antigen-specific T lymphocytes in mice and people. Because they may measure a wide range of immune responses and cellular immune-related activities, these tests are increasingly recommended and well-liked. Thus, ELISpot has now undergone a considerable transformation from a research tool to a clinical test that is often used in laboratories. Several ELISpot tests, including as those for IFN-gamma, Granzyme B, TGF-Beta 1, Fluorescent, and others, are used for a variety of diagnostic purposes. In order to conduct the FluoroSpot test, a 96-well plate containing a combination of monoclonal antibodies and PVDF membranes is used as the assay platform. For secreted proteins like cytokines from active cells, the ELISpot and FluoroSpot are ideally suited.
The worldwide ELISpot and FluoroSpot assay market is divided into infectious illnesses, cancer, autoimmune disorders, allergies, and others on the basis of diseases. The infectious illness is further divided into categories like COVID-19, the flu, HIV, and others. Due to the rising prevalence of chronic infectious illnesses and the higher productivity associated with the use of ELISpot and FluoroSpot tests, the infectious diseases sector is anticipated to dominate the ELISpot and FluoroSpot assay market in 2021. Diagnostic and research applications make up the segments of the global ELISpot and FluoroSpot assay market. Infectious illnesses, transplants, and other conditions are further divided into sub-segments within the diagnostic applications. The research applications are further divided into the following categories: cancer research, clinical trials, vaccine development, and others.
The COVID-19 pandemic had a major influence on healthcare systems across the world, including the markets for ELISpot and FluoroSpot assays. The FluoroSpot assay revealed that COVID-19 patients had the lowest antibody response, whereas three individuals (C4, C5, and C7) had the strongest T-cell responses. ELISpot and FluoroSpot tests are frequently used to evaluate COVID-19 patients' T- and B-cell immunity against SARS-CoV-2. Nonetheless, the industry has recorded a modest fall because COVID-19 instances decreased last year.
Request Sample Pages of Report: https://www.delvens.com/get-free-sample/elispot-and-fluorospot-assay-market-trends-forecast-till-2030
Delvens Industry Expert's Standpoint
The development of new vaccines to combat drug-resistant strains, the rise in the prevalence of chronic diseases worldwide, and technical advancements in ELISpot and FluoroSpot analyzers and assay kits are anticipated to propel market expansion. ELISpot is a vital technique in the creation of vaccines against a number of diseases, such as AIDS, TB, malaria, cancer, and the flu. In clinical investigations to assess vaccinations, the ELISpot test is frequently employed. In comparison to enzyme-linked immunoassays (ELISA) and flow cytometry, the FluoroSpot test based on the ELISpot was found to be more accurate in a June 2021 paper published in the BMC Infectious Diseases Journal (FCM). More than 15 million individuals between the ages of 30 and 69 pass away from NCDs, with low- and middle-income nations accounting for 85% of these early fatalities. As a result, the use of ELISpot and FluroSpot tests for diagnostic purposes is anticipated to expand due to the rising prevalence of chronic illnesses, fueling market expansion.
Key Findings
On the basis of application, The worldwide ELISpot and FluoroSpot test market is divided into diagnostic and research applications based on application. Infectious illnesses, transplants, and other conditions are further divided into sub-segments within the diagnostic applications. The research applications are further divided into the following categories: cancer research, clinical trials, vaccine development, and others. The market for ELISpot and FluoroSpot assays is predicted to be dominated by the diagnostic application sector in 2021 as a result of the rise in chronic infectious illnesses and the usage of point-of-care diagnostics during the pandemic.
On the basis of end user, The worldwide ELISpot and FluoroSpot assay market is divided into hospitals and clinics, research institutions, pharmaceuticals firms, and other end users based on end user. The ELISpot and FluoroSpot assay market is anticipated to be dominated by hospitals and clinics in 2021 as a result of the availability of improved diagnostic infrastructure and healthcare insurance policies.
The global ELISpot and FluoroSpot assay market is divided into direct tender and retail sales based on distribution. Due to the availability of a greater number of contacts, increased cost savings, and the assurance of compliance engagements, the direct tender sector is anticipated to dominate the market for ELISpot and FluoroSpot assays in 2021.
On the basis of product type, The worldwide ELISpot and FluoroSpot test market is divided into three categories based on the kind of product: assay kits, analyzers, and supplemental or ancillary products. The test kit products are further divided into t-cell and cell assays. Due to the increasing demand for cell-based assays in drug discovery and the usage of T-cell assays in cancer research, the assay kits sector is anticipated to dominate the ELISpot and FluoroSpot test market in 2021.
The global ELISpot and FluoroSpot assay market is divided into the following regions: the United States, Canada and Mexico; Germany, France, the United Kingdom; Italy; Spain; Russia; Belgium; Turkey; Switzerland; the Netherlands; and the rest of Europe; Japan; China; Australia; South Korea; India; Singapore; Thailand; Indonesia; Malaysia; the Philippines; and the rest of Asia-Pacific; Brazil; Argentina; and South Africa; as well as the rest of the Middle East and Africa.
Make an Inquiry Before Buying: https://www.delvens.com/Inquire-before-buying/elispot-and-fluorospot-assay-market-trends-forecast-till-2030
Regional Analysis
North America to Dominate the Market
Due to the widespread availability of ELISpot kits and the usage of the assay kits for vaccine research, North America is predicted to dominate the market.
Due to the availability of FDA-approved ELISpot and FluoroSpot assay kits, the existence of health reimbursement policies, the growth in chronic infections, and the rise in the older population, the U.S. is leading the worldwide ELISpot and FluoroSpot assay in the North America area.
Competitive Landscape
Oxford immunotec
Cellular Technology Limited
Mabtech
Becton
Abcam plc
Bio-Techne
Mikrogen Diagnostik
Autoimmun Diagnostika
U-CyTech
Medix Biochemica
Merck KGaA
Bio-Sys GmbH
Anogen-Yes Biotech Laboratories
Abnova Corporation
Biorbyt Ltd
Tokyo Chemical Industry
MP BIOMEDICALS
BOC Sciences
ZenBio,Inc
Jackson ImmunoResearch Inc
Krishgen Biosystems
National Analytical Corporation
Stemcell Technologies
Serva Electrophoresis GmbH
Recent Developments
In June 2022, In order to develop a molecular diagnostic test for the Monkeypox virus, an uncommon disease brought on by a virus closely related to the smallpox virus, BD and CerTest Biotec worked together. The partnership seeks to enhance the detection and treatment of infections with monkeypox. The assay will use the BD MAXTM open system reagent suite as part of the cooperation to validate the CerTest VIASURE Monkeypox CE/IVD molecular test on the BD MAXTM System. Users of BD MAXTM will have access to the test, which might increase knowledge of the disease's widespread distribution across the world.
In April 2022, A service for B-cell ELISpot assays was introduced by ProImmune Ltd. The body's immune defense against viruses, immunological modulators, vaccinations, and therapeutic medications depends heavily on B cells, which are analyzed with the B cell ELISpot test. By counting the amount of B cells that produce a particular antibody in response to a given stimulation, researchers may gauge the effectiveness of vaccinations or the strength of medicinal medications.
Purchase the Report at: https://www.delvens.com/checkout/elispot-and-fluorospot-assay-market-trends-forecast-till-2030
Reasons to Acquire
Increase your understanding of the market for identifying the most suitable strategies and decisions based on sales or revenue fluctuations in terms of volume and value, distribution chain analysis, market trends, and factors.
Gain authentic and granular data access for the ELISpot and FluoroSpot Assay Market to understand the trends and the factors involved in changing market situations.
Qualitative and quantitative data utilization to discover arrays of future growth from the market trends of leaders to market visionaries and then recognize the significant areas to compete in the future.
In-depth analysis of the changing trends of the market by visualizing the historic and forecast year growth patterns.
Report Scope
The ELISpot and FluoroSpot Assay Market is Segmented By Product, Application, End-User and region:
Based on Product Type
Analyzers
Assay kits
Ancillary Products
Based on the End-User
Hospitals & Clinical labs
Biopharmaceutical Company
Research Institutes
Based on the Application
Diagnostic Application
Research Application
Based on Disease
Infectious Disease
Cancer
Autoimmune Disease
Allergy
Other
Based on Source
Human
Mouse
Monkey
Others
Based on region
Asia Pacific
Japan
China
India
Australia
South Korea
Vietnam
New Zealand
Philippines
Thailand
Malaysia
Hong Kong
Taiwan
Singapore
Indonesia
Sri Lanka
Rest of Asia-Pacific
North America
U.S.
Canada
Mexico
Europe
Germany
U.K.
France
Italy
Spain
Sweden
Austria
Finland
Belgium
Turkey
Russia
Poland
Hungary
Czech Republic
Switzerland
Netherlands
Rest of Europe
South America
Brazil
Argentina
Chile
Colombia
Rest of South America
Middle East & Africa
South Africa
U.A.E.
Saudi Arabia
Oman
Qatar
Iran
Egypt
Rest of Middle East and Africa
The prominent players in the ELISpot and FluoroSpot Assay market are
Oxford immunotec
Cellular Technology Limited
Mabtech
Becton
Abcam plc
Bio-Techne
Mikrogen Diagnostik
Autoimmun Diagnostika
U-CyTech
Medix Biochemica
Merck KGaA
Bio-Sys GmbH
Anogen-Yes Biotech Laboratories
Abnova Corporation
Biorbyt Ltd
Tokyo Chemical Industry
MP BIOMEDICALS
BOC Sciences
ZenBio,Inc
Jackson ImmunoResearch Inc
Krishgen Biosysystems
National Analytical Corporation
Stemcell Technologies
Serva Electrophoresis GmbH
About Us:
Delvens is a strategic advisory and consulting company headquartered in New Delhi, India. The company holds expertise in providing syndicated research reports, customized research reports and consulting services. Delvens qualitative and quantitative data is highly utilized by each level from niche to major markets, serving more than 1K prominent companies by assuring to provide the information on country, regional and global business environment. We have a database for more than 45 industries in more than 115+ major countries globally.
Delvens database assists the clients by providing in-depth information in crucial business decisions. Delvens offers significant facts and figures across various industries namely Healthcare, IT & Telecom, Chemicals & Materials, Semiconductor & Electronics, Energy, Pharmaceutical, Consumer Goods & Services, Food & Beverages. Our company provides an exhaustive and comprehensive understanding of the business environment.
Contact Us:
UNIT NO. 2126, TOWER B,
21ST FLOOR ALPHATHUM
SECTOR 90 NOIDA 201305, IN
+44-20-8638-5055
0 notes
Text
Middle East and Africa Acetaminophen Reagents Market Analysis 2021, Size, Share, and Forecast by 2028
“The MEA acetaminophen reagents market is expected to grow from US$ 27.88 million in 2021 to US$ 36.54 million by 2028; it is estimated to grow at a CAGR of 3.9% from 2021 to 2028.”
The report titled “Middle East and Africa Acetaminophen Reagents Market” has recently been added by Business Market Insights to induce a stronger and more effective business outlook. It provides associate in-depth analysis of the various attributes of the industry, like trends, policies, and customers operational in several geographies. Research analysts use quantitative as well as qualitative analytical techniques to supply users, business owners, and industry professionals with accurate and actionable data. The Middle East and Africa Acetaminophen Reagents Market study provides comprehensive data which enhances the understanding, scope, and application during the forecast period.
Get a Sample Copy of Report, Click Here:
The Middle East and Africa Acetaminophen Reagents market following are the manufacturers cover –
Abbott
American Screening Corporation, Inc.
Beckman Coulter, Inc.
Bio-Rad Laboratories, Inc.
Biorbyt Ltd.
Randox Laboratories, Ltd.
Siemens Healthineers AG
Thermo Fisher Scientific Inc.
The leading players of the Middle East and Africa Acetaminophen Reagents industry, their market share, product portfolio, company profiles are covered during this report. Key market players are analyzed on the basis of production volume, gross margin, market value, and price structure. The competitive market scenario among Middle East and Africa Acetaminophen Reagents players will help the industry aspirants in planning their strategies. The statistics presented in this report are an accurate and helpful guide to shaping your business growth.
Middle East and Africa Acetaminophen ReagentsMarket Split by Product Type and Applications:
This report segments the Middle East and Africa Acetaminophen Reagents Market on the basis of Types are:
Antibody/Substrate Reagent
Enzyme Reagent
Acetaminophen Antiserum
Acetaminophen Fluorescein Tracer
Pretreatment Solution
On the basis of Application, the Middle East and Africa Acetaminophen Reagents Market is segmented into:
Enzymatic Assays
Immunoassay
This analysis report also presents practical and practical case studies to help you get a clearer understanding of the subject. This analysis report has been prepared through industry analysis techniques and presented in a professional manner by including effective information graphics whenever necessary. It helps ensure business stability and rapid development to achieve notable remarks within the Middle East and Africa Acetaminophen Reagents market.
Table of Contents: Middle East and Africa Acetaminophen Reagents Market
Chapter 1: Overview of Middle East and Africa Acetaminophen Reagents
Chapter 2: Regional Market Status and Forecast by Regions
Chapter 3: Regional Market Status and Forecast by Types
Chapter 4: Regional Market Status and Forecast by Downstream Industry
Chapter 5: Market driving correlational analysis
Chapter 6: Market competition status by major makers
Chapter 7: Major manufacturer��s introduction and market data
Chapter 8: Upstream and downstream market analysis
Chapter 9: Cost and gross margin analysis
Chapter 10: Marketing status analysis
Chapter 11: Market report conclusion
Chapter 12: Research methodology and reference
Click Here to Buy Now:
Note: This report may be customized to suit your requirements. Get in touch with our sales team so you can get a report tailored to your needs.
About Us:
Business Market Insights is a market research platform that provides subscription services for industry and company reports. Our research team has extensive professional expertise in domains such as Electronics & Semiconductors; Aerospace & Defense; Automotive & Transportation; Energy & Power; Healthcare; Manufacturing & Construction; Food & Beverages; Chemicals & Materials; and Technology, Media, & Telecommunications.
Contact Us:
If you have any questions about this report or would like further information, please contact us:
Contact person: Ankit Mathur
Email: [email protected]
Phone: +16467917070
0 notes
Text
Key Players In United States Enzyme-Linked Immunosorbent Assay Market, Segmentation, Size, Shares, And Revenue Analysis
The ELISA is an immunological assay commonly used for the detection of antibodies, antigens, proteins and glycoproteins which are prone to present in the biological samples. Some of examples includes the diagnosis of HIV infection, pregnancy test and measurement of cytokines or soluble receptors in the biological liquid samples. ELISA assay are generally carried out in 96 well plates which allows multiple samples to be measured in a single experiment. These plates must be special absorbant plates like immune plates for ensuring the sticking of antigen or antibody to the surface. Every ELISA measures a specific antigen and kits for a variety of antigens are widely available.
To know the scope of our report get a sample on https://www.axiommrc.com/request-for-sample/11122-united-states-enzyme-linked-immunosorbent-assay-market-report
MARKET DYNAMICS- UNITED STATES ENZYME-LINKED IMMUNOSORBENT ASSAY MARKET
The United States enzyme-linked immunosorbent assay market is witnessing lucrative growth during the forecast period of 2019 - 2028. The ELISA based on the principle that specific antibodies bind the target and detect the presence and quality of antigen binding. In order to increase the sensitivity along with precision of the assay, the plate must be coated with antibodies whose having high affinity. The dynamic factors such as increasing cases of infectious diseases is propelling growth of United States enzyme-linked immunosorbent assay market. Furthermore, continuous development of innovative and novel products by key players is also boosting growth of United States enzyme-linked immunosorbent assay market. However, presence of other immunoassay techniques is hindering growth of United States enzyme-linked immunosorbent assay market.
COVID-19 IMPACT ON UNITED STATES ENZYME-LINKED IMMUNOSORBENT ASSAY MARKET
The exclusive COVID-19 impact analysis report by Axiom MRC provides a 360 degree analysis of micro and macro-economic factors on the Enzyme-linked immunosorbent assay market. In addition, complete analysis of changes on Enzyme-linked immunosorbent assay expenditure, economic and international policies on supply and demand side. The report also studies the impact of pandemic on United States economies, international trade, business investments, GDP and marketing strategies of key players present in the market. The COVID-19 has almost affected every market is healthcare industries positively or negatively. The rising cases of COVID-19 and adoption of technically advanced test for detection of infectious diseases in patients is rising demand of Enzyme-linked immunosorbent assay. The Enzyme-linked immunosorbent assay test is more sensitive than other tests for detection of infectious disease in patients. Thereby, the Enzyme-linked immunosorbent assay market has positive impact of COVID-19.
UNITED STATES ENZYME-LINKED IMMUNOSORBENT ASSAY MARKET- SEGMENTAL OVERVIEW
The United States enzyme-linked immunosorbent assay market is bifurcated into type, application and end user.
UNITED STATES ENZYME-LINKED IMMUNOSORBENT ASSAY MARKET BY TYPE
Based on type, the United States enzyme-linked immunosorbent assay market is segmented into the sandwich ELSIA, indirect ELSIA, direct ELSIA, competitive ELSIA. In which indirect ELSIA is estimated to dominate the market in 2020. The indirect ELISA test is also referred as two step ELISA which includes two binding process of primary antibody and labelled secondary antibody. The primary antibody is incubated with antigen followed by the incubation with the secondary antibody.
UNITED STATES ENZYME-LINKED IMMUNOSORBENT ASSAY MARKET BY APPLICATION
Based on application, the United States enzyme-linked immunosorbent assay market is bifurcated into the vaccine development, immunology, diagnostics, toxicology, drug monitoring and pharmaceuticals and transplantation. In which drug monitoring and pharmaceuticals is also contributing to the growth of market in 2020. The ELISA technique allows the identification and quantification of previously known proteins to be ascertained by immunological means. The key to ELISA is linking of antibody to the enzyme which is capable of catalyzing a colorimetric or chemiluminescent reactions.
UNITED STATES ENZYME-LINKED IMMUNOSORBENT ASSAY MARKET BY END USER
Based on end user, the United States enzyme-linked immunosorbent assay market is categorised into the hospital and diagnostic centres, research laboratories and other. In which hospital and diagnostic centres are likely to dominate the market in 2020. The increasing flow of patients in hospital and diagnostic centres is propelling growth of enzyme-linked immunosorbent assay market. The rising number of hospitals and diagnostic centres is also boosting growth of enzyme-linked immunosorbent assay market. The rising demand for quality testing is also refuelling growth of enzyme -linked immunosorbent assay market.
KEY PLAYERS IN ENZYME-LINKED IMMUNOSORBENT ASSAY MARKET
The major key players of Enzyme-linked immunosorbent assay market are Alpco, Abcam Plc, Agilent Technologies Inc., BD Biosciences, Bio-Rad Laboratories Inc., Biolegend Inc., Enzo Life Sciences Inc., F. Hoffmann-La Roche Ltd., Merck Kgaa, Mercodia Ab, Ortho-Clinical Diagnostics Inc., Perkinelmer Inc., Qiagen Nv, R&D Systems Inc., Shenzen Yhlo Biotech Co. Ltd., Thermo Fischer Scientific Inc., Zeus Scientific, Inc. and Biomérieux Sa among others.
KEY DEVELOPMENTS IN ENZYME-LINKED IMMUNOSORBENT ASSAY MARKET
February 2021: The Thermo Fisher Scientific Inc., acquired the private point of care molecular diagnostic company named as Mesa Biotech.
February 2020: The Becton Dickinson and Co. reported a collaborated with Babson Diagnostic for bringing lab quality, little volume blood assortment to retail drug stores.
March 2018: BARD1 Life sciences, The U.S. based science research company is expected the commercialization of BARD1-Ovarian blood based ELSIA test for distinguishing ovarian diseases in the beginning phase.
January 2018: The Eagle Biosciences Inc., presented a novel unblemished FGF23 ELISA unit test which is the 96 well sandwich ELISA examination. It is estimated as full-length dynamic type of human Intact FGF23 utilized for the discovery of mineral bone disorder, chronic kidney disorder, chronic kidney disease and hyperphosphatemia.
Buy now United States Enzyme-Linked Immunosorbent Assay Market Report https://www.axiommrc.com/buy_now/11122-united-states-enzyme-linked-immunosorbent-assay-market-report
About Us:
Axiom Market Research & Consulting™ is a full-service market research and data analytics company providing key market intelligence to global companies to take informed business decisions pertaining to their marketing strategy, investments, new product launches, market competition, consumer or end users, social media trends etc.
Axiom Market Research & Consulting™ offers market research services such as syndicated market research, custom market research, business consulting, and consumer/end user surveys. Under Business to Consumer (B2C) market research offerings, Axiom MRC assists its clients in finding quantitative information/preferences of its brands and services such as, awareness, usages, satisfaction, tracking, ethnicity etc. Axiom MRC offers data collection services through online surveys, social media, data processing and interpretation.
Axiom MRC with its experienced team of research and data analysts, has delivered more than 5000+ Market Research Projects, 3800+ Data Analytics Projects, 1200+ Business Support Projects and has a 800+ Global Client Base. Axiom Market Research & Consulting™ aims to become the preferred market research and data analytics company by providing key market intelligence solutions for client’s business growth.
Contact Us:
Axiom Market Research & Consulting™
3 Germay Dr. Ste 4 - 4666
Wilmington DE 19804
U.S.:- + 1 (845) 875-9786
U.K.:- + 44 (0) 20 3286 9707
Email: [email protected]
Website: https://www.axiommrc.com/
Blog: https://industrywatch24.com/
Follow On
LinkedIn: https://www.linkedin.com/company/axiom-market-research-and-consulting/
Twitter: https://twitter.com/AxiommrcCom
0 notes